Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using a two-dose primary protocol in children and adolescents (Immunita-002, Brazil): a phase IV one-year follow-up
Immunogenität und Sicherheit des inaktivierten SARS-CoV-2-Impfstoffs (CoronaVac) mit Zwei-Dosen-Primärschema bei Kindern und Jugendlichen (Immunita-002, Brasilien): 1-Jahres-Follow-up einer Phase-IV-Studie
Frontiers in Immunology · 11.11.2026 · 17
DOI: 10.3389/fimmu.2026.1968416 ↗Auf einen Blick
Bei 640 Kindern und Jugendlichen blieben die humoralen Antworten 12 Monate nach zwei Dosen CoronaVac hoch. Zusätzlich zeigten sich anhaltende Veränderungen der antigenstimulierten Immunaktivität.
Fragestellung
Wie langlebig sind Immunogenität und Sicherheit von CoronaVac 12 Monate nach dem Zwei-Dosen-Primärschema bei Kindern und Jugendlichen?
Methode
Phase-IV-Längsschnittstudie bei 640 Kindern und Jugendlichen 3–17 Jahre; Follow-up über 12 Monate; Messung humoraler und zellulärer Immunität sowie Sicherheit.
Ergebnisse
Anti-S- und Anti-N-IgG-Seropositivität blieb hoch (90–96 % bzw. 93–98 %). Neutralisierende AK gegen B.1 blieben hoch; bei 3–11-Jährigen sank die Seropositivität auf 80 % nach 12 Monaten. BA.5 erreichte 100 %.
Einschränkungen
Mechanismen des Immungedächtnisses und der Zusammenhang zwischen Immunantworten und klinischem Schutz bleiben ungeklärt.
Schlussfolgerung der Autor:innen
CoronaVac induzierte anhaltende humorale Antworten und war mit longitudinalen Veränderungen der antigenstimulierten Immunaktivität über 12 Monate verbunden.
Kernaussagen
- Anti-S- und Anti-N-IgG-Seropositivität blieb 12 Monate hoch.
- Neutralisation gegen BA.5 erreichte nach 12 Monaten 100 %.
- Keine weiteren unerwünschten Ereignisse in den letzten 6 Monaten.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Studienprotokoll in der Zeitschrift Frontiers in Immunology, online erschienen am 11.11.2026. Verfasst von Camila Amormino Corsini und 31 weiteren Autor:innen. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Long-term evidence on the durability and quality of immune responses induced by the inactivated whole-virus CoronaVac vaccine in children and adolescents remains limited. We evaluated humoral and cellular immunity and safety over 12 months after completion of the primary vaccination schedule. In this phase IV longitudinal study, 640 children and adolescents aged 3–17 years who received two doses of CoronaVac were followed for 12 months. Humoral immunity was assessed by anti-Spike (anti-S) and anti-Nucleocapsid (anti-N) IgG ELISAs and neutralizing antibody assays against the ancestral SARS-CoV-2 B.1 lineage and Omicron BA.1 and BA.5 subvariants. Cellular immunity was evaluated through antigen-specific stimulation of peripheral blood mononuclear cells, multiplex quantification of soluble immune mediators, and immune network analysis. Safety and suspected COVID-19 cases were monitored throughout follow-up. Anti-S and anti-N IgG seropositivity remained high throughout follow-up (90-96% and 93-98%, respectively). Neutralizing antibodies against the ancestral B.1 lineage remained high in both age groups, although seropositivity decreased to 80% at 12 months among children aged 3–11 years. In contrast, cross-neutralization against Omicron BA.5 increased over time, reaching 100% seropositivity in both age groups at 12 months. Vaccination was associated with changes in chemokines, inflammatory and regulatory cytokines, and growth factors, alongside dynamic immune network remodeling. Antigen-specific PBMC stimulation demonstrated cytokine and chemokine responses one year after vaccination, with distinct profiles following ancestral and Omicron Spike stimulation. No additional adverse events were reported during the final six months. Previously reported serious adverse events resolved without vaccine-related sequelae, and no clinically reported COVID-19 cases occurred during the final six months of surveillance. CoronaVac induced persistent humoral responses and was associated with longitudinal changes in antigen-stimulated immune activity over 12 months. Integrated immunological analyses provide insights into the durability and coordination of immune responses following primary vaccination in children and adolescents, while the mechanisms underlying immune memory and the relationship between immune responses and clinical protection remain to be elucidated.
Zitieren
APA
Corsini, C. A., Martins, P. F. D. S., Filgueiras, P. S., Lourenço, A. J., Lima, A. E. D. S., Jeremias, W. D. J., Alves, P. A., Fernandes, G. D. R., Castro, L. L. M. E., Teixeira-Carvalho, A., Campi-Azevedo, A. C., Magalhães-Gama, F., Miranda, V. H. S., Costa-Pereira, C., Curimbaba, C. D. A. L., Lorencini, D. A., Junior, E. M., Silva, V. M. D., Cervi, M. C., …, & Grenfell, R. F. Q. E. (2026). Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using a two-dose primary protocol in children and adolescents (Immunita-002, Brazil): a phase IV one-year follow-up. Frontiers in Immunology, 17. https://doi.org/10.3389/fimmu.2026.1968416
Vancouver
Corsini CA, Martins PFDS, Filgueiras PS, Lourenço AJ, Lima AEDS, Jeremias WDJ, et al. Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using a two-dose primary protocol in children and adolescents (Immunita-002, Brazil): a phase IV one-year follow-up. Frontiers in Immunology. 2026;17. doi:10.3389/fimmu.2026.1968416
BibTeX
@article{Corsini2026,
author = {Corsini, Camila Amormino and Martins, Priscila Fernanda da Silva and Filgueiras, Priscilla Soares and Lourenço, Adelina Júnia and Lima, Ana Esther de Souza and Jeremias, Wander de Jesus and Alves, Pedro Augusto and Fernandes, Gabriel da Rocha and Castro, Luciana Lisboa Mota e and Teixeira-Carvalho, Andrea and Campi-Azevedo, Ana Carolina and Magalhães-Gama, Fábio and Miranda, Vitor Hugo Simões and Costa-Pereira, Christiane and Curimbaba, Caroline De Almeida Leitao and Lorencini, Daniela Aparecida and Junior, Eolo Morandi and Silva, Victor Mattos da and Cervi, Maria Célia and Borges, Marcos de Carvalho and Lima, Poliana Remundini de and Nascimento, João Paulo Resende do and Nogueira, Maurício Lacerda and Campos, Guilherme Rodrigues Fernandes and Correa, Paulo Roberto Lopes and Carvalho, Taciana Malheiros Lima and Reis, Jordana Grazziela Alves Coelho dos and Reis, Erik Vinícius de Sousa and Castilho, Leda dos Reis and Oliveira, Jaquelline Germano de and Martins-Filho, Olindo Assis and Grenfell, Rafaella Fortini Queiroz e},
title = {Immunogenicity and safety of inactivated SARS-CoV-2 vaccine (CoronaVac) using a two-dose primary protocol in children and adolescents (Immunita-002, Brazil): a phase IV one-year follow-up},
journal = {Frontiers in Immunology},
year = {2026},
volume = {17},
doi = {10.3389/fimmu.2026.1968416}
}
EUVIMED